Wells Fargo downgraded Penumbra (PEN) to Equal Weight from Overweight with a $374 price target after Boston Scientific (BSX) entered an agreement to acquire Penumbra in a cash and stock transaction valued at $14.5 billion, or $374 per share.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Penumbra rises 11.9%
- M&A News: Penumbra Stock (PEN) Beats Harder on $14.5B Boston Scientific (BSX) Acquisition
- Penumbra downgraded to Neutral from Overweight at Piper Sandler
- Penumbra downgraded to Market Perform from Outperform at William Blair